Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women

Endocrine

Volumn 23, Issue 2-3, 2004, Pages 215-218

  Cheng, Wern Cherng ^a   Yen, Men Lu ^a   Hsu, Sandy H J ^a   Chen, Kuang Ho ^a,b   Tsai, Keh Sung ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

FSH; LH; Prolactin; Raloxifene

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE; PROLACTIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPEPSIA; FEMALE; FLATULENCE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS; LUTEINIZING HORMONE BLOOD LEVEL; NORMAL HUMAN; OSTEOPOROSIS; OVARY; POSTMENOPAUSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; STATISTICAL SIGNIFICANCE; BLOOD; DRUG ANTAGONISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OVARY; PITUITARY GLAND; POSTMENOPAUSE; PROLACTIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 4243079985     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1385/ENDO:23:2-3:215     Document Type: Article

References (21)

1. Brown, J. P. and Josse, R. G. (2002). Can. Med. Assoc. J. 167(10 Suppl.).
2. Beresford, S. A. A., Weiss, N. S., Voigt, L. F., and McKnight, B. (1997). Lancet 349, 458-461.
3. Collaborative group on hormonal factors in breast cancer. (1997). Lancet 350, 1047-1059.
4. Writing group for the women's health initiative investigators. (2002). J. Am. Med. Assoc. 288, 321-333.
5. Shumaker, S. A., Legault, C., Rapp, S. R., et al. (2003). J. Am. Med. Assoc. 289, 2651-2662.
6. Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., et al. (1997). N. Engl. J. Med. 337, 1641-1647.
7. Enmark, E. and Gustafsson, J. A. (1999). J. Inter. Med. 246, 133-138.
8. Ettinger, B., Black, D. M., Mitlak, B. H., et al. (1999). J. Am. Med. Assoc. 282, 637-645.
9. Alvarez-Tutor, E., Forga-LLenas, L., Rodriguez-Erdozain, R., Goni-Iriarte, M. J., Mendendez-Torre, Z., and Alvarez-Tutor, J. (1999). Arch. Gynecol. Obstet. 263, 45-50.
10. Kostoglou-Athanassiou, I., Ntalles, K., Gogas, J., et al. (1997). Horm. Res. 47, 116-120.
11. Tsai, K. S., Yen, M. L., Pan, H. A., et al. (2001). Osteoporos. Int. 12, 1020-1025.
12. Grady, D., Wenger, N. K., Herriton, D., et al. (2000). Ann. Inter. Med. 132, 689-696.
13. Paech, K., Webb, P., Kuiper, G. G. J. M., et al. (1997). Science 277, 1508-1510.
14. Cummings, M., Eckert, S., Krueger, K. A., et al. (1999). J. Am. Med. Assoc. 281, 2189-2197.
15. Aron, D. C., Finding, J. W., and Tyrrell, J. B. (2001). In: Basic and clinical endocrinology. Greenspan, F. S. and Gardner, D. G. (eds.). McGraw Hill: New York, NY.
16. Lewinthal, D., Corenblum, B., and Taylor, P. J. (1987). Int. J. Fertil. 32, 185-191.
17. Klinge, C. M. (2000). Steroids 265, 227-251.
18. Lasco, A., Cannavo, S., Gaudio, A., et al. (2002). J. Endocrinol. Invest. 25, S95-S96.
19. Uebelhart, B., Bonjour, J. P., Draper, M., Pavo, I., and Rizzoli, R. (2001). Osteoporos. Int. 12, S77.
20. Palomba, S., Orio, F. Jr., Morelli, M., et al. (2002). J. Clin. Endocrinol. Metab. 87, 3603-3608.
21. The writing group for PEPI trial. (1995). J. Am. Med. Assoc. 273, 199-208.